World-first RNA discovery could lead to potential new breast cancer therapy
A newly discovered long noncoding RNA molecule selectively kills hormone‑receptor positive breast cancer cells and activates the immune system, presenting a potential RNA‑based therapy for HR+ breast cancer.
Researchers at QIMR Berghofer identified a long non‑coding RNA that specifically kills hormone‑receptor positive breast cancer cells and induces immune activation, indicating it could become a novel RNA‑based therapy for HR+ breast cancer.
This discovery offers a new therapeutic avenue for patients with hormone‑receptor positive breast cancer who develop resistance to existing treatments, potentially combining targeted cytotoxicity with immune system engagement.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC